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Sepsis is a highly complex, life-threatening syndrome that develops when the bodies’ 
immune response to an infection causes injury to its own tissues and organs. The course 
and outcome of sepsis is highly heterogeneous and depends on complex host-pathogen 
interactions, the pathogen, and timing of diagnosis and effective treatment [1, 2]. Patients 
at risk for sepsis may benefit from personalized diagnostic assessment and treatment 
strategies. Multiple attempts have failed to develop classical biomarkers from e.g. serum 
to diagnose sepsis – also due to the heterogeneity of presentation. Digital biomarkers in 
sepsis may offer a different approach, as the collection of very large datasets allows to 
integrate time-series data of directly measured physiological parameters [3]. Within an 
integrative approach, digital biomarkers may be combined with -omics biomarkers (e.g. 
metabolomics, metagenomic, whole genome sequencing of bacteria, immune 
phenotyping) and form hybrid biomarkers with higher sensitivity and specificity. The 
use of novel machine-learning based algorithms to explore such datasets may help to 
better understand the data and discover patterns within the data linked to particular 
clinical phenotypes [2]. These algorithms may potentially allow to guide tailored 
personalized treatment strategies in sepsis. We aim to build a network for data-driven 
and -omics technology-based research to (i) recognize sepsis at an earlier stage and (ii) 
predict risk of mortality. 
2.Methods 
In the driver project funded by the Swiss Personalized Health Network (SPHN) and 
Personalized Health Related Technologies (PHRT), each University Hospital (Basel, 
Bern, Geneva, Lausanne and Zurich) and University of Bern and Zurich will provide 
data from critically ill patients hospitalized in intensive care units (ICUs).  
The locally generated data is collected from various hospital information 
systems (IS) such as clinical and laboratory IS, devices such as ventilators and dialysis 
machines, ICU monitors, and treatment-related data, e.g. drug doses and transferred and 
stored in local clinical data warehouses (CDWH). In order to follow Sepsis 3.0 criteria 
[4], we regularly tag patient with suspected sepsis and collect information in the clinical 
IS. This will allow to compute Sepsis-3 criteria and compare data patterns to this 
international accepted definition of sepsis. The data is structured and interoperable 
between centres following SNOMED CT and LOINC ontologies. Data is then transferred 
in a resource description framework (RDF) format after encoding and encryption via the 
BioMedIT nodes to the ETH domain for further analysis. A shared data model will be 
used for machine-learning based analysis. The legal and governance framework is 
established using a Data Transfer and Use Agreement (DTUA) and Consortium 
Agreement (CA) [Figure 1]. 
The clinical outcomes of our study include: (i) prediction of sepsis with new 
markers in comparison to Sepsis-3 criteria and (ii) prediction of in-hospital mortality. 
There are two prospective observational trials conducted with these patients. 
Study A includes every patient admitted to an ICU. Following specific 
inclusion/exclusion criteria, we include sepsis (cases) and non-sepsis (controls) upon 
entry of the ICU. Of all patients with an ICU admission also available pre/post-ICU data 
will be integrated into the data analysis. We will compare data patterns between cases 
and controls in regards of the previously defined outcomes. 
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Study B includes a subgroup of the patients from Study A. In all five hospitals 
a total of 300 patients with severe community acquired pneumonia (cases) and 100 
patients with a severe systemic inflammation (controls) will be included. We will collect 
additional patient material such as serum, whole blood for DNA and RNA, respiratory 
and stool material, immune cells and bacterial isolates. These samples will be in-depth 
characterized using metabolomics, metagenomics, whole genome sequencing and 
immune phenotyping technologies. Digital and -omics data will then be merged and 
analysed to form hybrid biomarkers. Again, case and control patients will be compared 
in regards of the previously defined outcomes. 
3.Results 
For the digital biomarker project (Study A) we have obtained ethical approval to collect 
data from 15,000 ICU patients from participating centres over the next few years. In 
addition, a data transfer and use agreement as well as a consortium agreement have been 
generated. The legal process to allow data sharing was complex and involved a multiple 
round assessment and discussion of the legal framework with various stakeholders. 
 A list of clinical, physiological and laboratory variables, covering more than 
500 attributes of interest was generated and linked to ontologies such as time points, 
application route and dosage of specific drugs, etc. Collection of data has started at local 
levels with a total of already several hundred patients from the participating ICUs. Within 
the next 6 months, we expect data from 3,000 patients to be collected.  
 Data transfer and exchange protocols are currently tested with all CDWH, 
BioMedIT, and ETH domain teams and continuously improved.  
 The second -omics biomarker project (Study B) has not yet started. The ethical 
proposal has been submitted and decision is pending. Study preparation are progressing 
at all centers. In regards of the sample management different biobank information 
management software (BIMS) systems have been established in the various centers.  
4.Conclusions 
Ethical and legal frameworks are critical in a data-driven large consortium and this 
bottleneck should not be underestimated. The legal discussions show a different 
momentum, content and motivation compared to research questions. This should be 
anticipated in such a project. A lead legal institution may be a good concept to provide 
legal advice, besides the availability of the DTUA and CA. The legal situation of large 
healthcare project is complex and requires a professional support. There is a clear benefit 
of regular meetings with all stakeholders for in-depth discussions and finding solutions 
for challenges. Once fully functional, the current framework will allow to collect and 
store data for research purposes across all Swiss University Hospitals ICUs – beyond 
sepsis. 
A. Egli et al. / SPHNPHRT: Forming a Swiss-Wide Infrastructure 1165
 
Figure 1. SPHN/PHRT framework for the Sepsis driver project. All centers locally collect data from 
different primary sources in clinical data warehouses. The is high interoperable and standardized 
following ontologies. The exchanged follows secured routes of BioMedIT to the ETH Domain for quality 
control and analysis. [1] 
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